Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2005-11-17 (20 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: RENNES (35000), Ille-et-Vilaine
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE DE VILLEJEAN : revenue, balance sheet and financial ratios
SELARL PHARMACIE DE VILLEJEAN is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in RENNES (35000),
this company of category PME
shows in 2025 a net income positive of 146 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DE VILLEJEAN (SIREN 485070320)
Indicator
2025
2024
2023
2021
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
146 095 €
107 131 €
89 653 €
204 607 €
252 888 €
254 018 €
251 746 €
213 379 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DE VILLEJEAN generates positive net income of 146 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 213 k€ -> 146 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
146 095 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 25%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 71%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
24.653%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
70.59%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DE VILLEJEAN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2021
2023
2024
2025
Debt ratio
0.0
64.51
57.881
50.419
40.649
28.281
26.351
24.653
Financial autonomy
51.3
56.904
60.369
61.791
66.488
73.467
69.92
70.59
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
24.652025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of SELARL PHARMACIE DE VILLE... (24.65) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
70.59%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of SELARL PHARMACIE DE VILLE... (70.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 208.97. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
208.969
Liquidity indicators evolution SELARL PHARMACIE DE VILLEJEAN
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2021
2023
2024
2025
Liquidity ratio
311.204
161.043
237.707
153.416
280.138
294.157
196.577
208.969
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
208.972025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good-16 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE DE VILLE... (208.97) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of SELARL PHARMACIE DE VILLEJEAN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DE VILLEJEAN is estimated at
2 320 736 €
(range 1 574 862€ - 3 641 555€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1574k€2320k€3641k€
2 320 736 €Range: 1 574 862€ - 3 641 555€
NAF 5 année 2025
Valuation method used
Net Income Multiple
146 095 €
×
15.9x
=2 320 736 €
Range: 1 574 863€ - 3 641 555€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DE VILLEJEAN with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DE VILLEJEAN
What is the revenue of SELARL PHARMACIE DE VILLEJEAN ?
The revenue of SELARL PHARMACIE DE VILLEJEAN is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE DE VILLEJEAN profitable?
Yes, SELARL PHARMACIE DE VILLEJEAN generated a net profit of 146 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DE VILLEJEAN ?
The headquarters of SELARL PHARMACIE DE VILLEJEAN is located in RENNES (35000), in the department Ille-et-Vilaine.
Where to find the tax return of SELARL PHARMACIE DE VILLEJEAN ?
The tax return of SELARL PHARMACIE DE VILLEJEAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DE VILLEJEAN operate?
SELARL PHARMACIE DE VILLEJEAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart